To convert the meeting times to your local time Click Here
Industry Hall 2
Ovarian cancer, the second most common gynecologic cancer, leads to more deaths than any other cancer of the female reproductive system. Effective and well-tolerated treatments for platinum-resistant ovarian cancer (PROC) remain a substantial medical need, as the current standard of care of single agent chemotherapy has limited efficacy (≤12% response rates) and is associated with significant systemic toxicities. Antibody Drug Conjugates (ADCs) are emerging as a novel class of agents for the treatment of PROC. ADCs work by targeting specific antigens on the tumor cell to deliver, in most cases, a cytotoxic payload.This symposium will focus on the potential role for ADCs in the treatment paradigm of PROC. A panel of experts will review the structure, payload, mechanism of action, and relevant targets of various ADC technologies and discuss the balance of traits needed to achieve a desired therapeutic index. Biomarkers and diagnostic assays that may aid in patient selection for clinical trials in PROC will be examined. The session will conclude with emerging clinical data and ongoing trials of investigational ADCs targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in ovarian cancer with limited expression in normal tissue.